Nanosuspension technology and its applications in drug delivery

Main Article Content

N Arunkumar
M Deecaraman
C Rani


Solubility is an essential factor for drug effectiveness, independent of the route of administration. Poorly soluble drugs are often a challenging task for formulators in the industry. Conventional approaches for enhancement of solubility
have limited applicability, especially when the drugs are poorly soluble simultaneously in aqueous and in non-aqueous media. Nanosuspension technology can be used to improve the stability as well as the bioavailability of poorly soluble
drugs. Nanosuspensions are biphasic systems consisting of pure drug particles dispersed in an aqueous vehicle, stabilized by surfactants. These are simple to prepare and are more advantageous than other approaches. Techniques such as wet milling, high-pressure homogenization, emulsification–solvent evaporation and super critical fluid have been used in the preparation of nanosuspensions. It has the advantage of delivery by various routes, including oral, parenteral, pulmonary and ocular routes. The present article reviews the current methods used to prepare nanosuspensions and their application in drug delivery.


Download data is not yet available.

Article Details

How to Cite
Arunkumar, N., Deecaraman, M., & Rani, C. (2014). Nanosuspension technology and its applications in drug delivery. Asian Journal of Pharmaceutics (AJP), 3(3).


The Biopharmaceutics Classification System (BCS) Guidance, Office of

Pharmaceutical Science. Available from:

BCS_guidance.htm [last accessed on 2008 Jan 12].

Clewlow PJ. Survival of the smartest. Scrip’s Target world drug delivery

news 2004;35:316-23.

Seedher N, Kaur J. Solubilization of nimesulide; use of co-solvents. IJPS


Mersiko-Liversidge E, MGurk SL, Liversidge GG. Insulin nanoparticles:

A novel formulation approach for poorly water soluble Zn-Insulin.

Pharm Res 2004;21:1545-53.

Benjamin C-Y Lu, Dingan Zang, Wei Sheng. Solubility enhancement in

supercritical fluids. Pure and Appl Chem 1990;62:2277-85.

Abu T. M. Serajuddin. Solid dispersion of poorly soluble drugs-Early

promises, subsequent problems, and recent breakthroughs. J Pharm

Sci 2000;88:1058-66.

Frömming KH. Cyclodextrine-eine vielseitig verwendbare Gruppe neuer

Hilfsstioffe. In: Muller RH, Hildebrand GE, editors. Pharmazeutische

Technologie; Modern Arzneiformen, 2nd ed. Stuttgart: WVG; 1998.

Sucker H. Hydrosole, eine Alternative für die parenterale Anwendung

von schwer wasserloslichen Wirkstoffen. In: Muller RH, Hildebrand GE,

editors. Pharmazeutische Technologie; Modern Arzneiformen. 2nd ed.

Stuttgart: WVG; 1998.

Dubey R. Pure drug nanosuspensions-Impact of nanosuspension technology on drug discovery and development. Drug Del Tech 2006;6:65-71.

Muller RH Peters K, Becker R, Kruss B. Nanosuspension for IV

administration of poorly soluble drugs-Stability during sterilization and

long term storage. Proc Int Symp Control Rel Bioact Mater 1995;22:574-5.

Müller RH, Grau MJ, Hildebrand GE. Increase of solubility of poorly

soluble drugs by transfer to Dissocubes using high pressure

homogenization. Proc Int Symp Control Rel Bioact Mater 1999;26:112-3.

Schöler N, Krause K, Kayser O, Müller RH, Borner K, Hahn H, et al.

Atovaquone nanosuspensions show excellent therapeutic effect in a

new murine model of reactivated toxoplamosis. Antimicrob Agents

Chemother 2001;45:1771-9.

Radtke M. Nanopure: pure drug nanoparticles for the formulation of

poorly soluble drugs. New Drugs 2001;3:62-8.

Dearns R. Atovaquone pharmaceutical compositions. US Patent US

, 2000.

Young TJ, Mawson S, Johnston KP, Henriska IB, Pace GW, Mishra AK.

Rapid expansion from supercritical to aqueous solution to produce

submicron suspension of water insoluble drugs. Biotechnol Prog


Chattopadhyay P, Gupta RP. Production of griseofulvin nanoparticles

using supercritical CO2 antisolvent with enhanced mass transfer. Int

J Pharm 2001;228:19-31.

Bohm BH, Muller RH. Lab-scale production unit design for nanosuspensions of sparingly soluble cytotoxic drugs. PSTT 1999;2:336-9.

Muller RH, Becker R, Kross B, Peters K. United States Patent No.5858410.January 12, 1999.

Setler P. Identifying new oral technologies to meet your drug delivery

needs for the delivery of peptides and proteins and poorly soluble

molecules. IIR Limited, Drug delivery systems London: 1999.

Liversidge GC. Paper presented at the 23rd International symposium

of the Controlled Release Bioactive Materials Society. Workshop on

Particulate Drug Delivery Systems; 1996.

Kayser O, Olbrich C, Yardley V, Kiderten Ap, Croft SL. Formulation of

amphotericin-B as nanosuspension for oral administration. Int J Pharm


Chen Y, Liu J, Yang X, Zhao X, Xu H. Oleanolic acid nanosuspensions:

Preparation, in vitro characterization and enhanced hepato protective

effect. J Pharm Pharmacol 2005;57:259-64.

Kocbek P, Baumgartner S, Kristi J. Preparation and evaluation of

nanosuspensions for enhancing dissolution of poorly soluble drugs.

Int J Pharm 2006;312:179-86.

Langutth P, Hanafy A, Frenzel D, Grenier P, Nhamias A, Ohlig T, et al.

Nanosuspension formulation for low soluble drugs: Pharmacokinetics

evaluation using spiranolactone as model compound. Drug

Dev Ind Pharm 2005;31:319-29,

Peters K, Leitzke S, Diederichs JE, Borner K, Hahn H, Müller RH, et al.

Preparation of a clofazimine nanosuspensions for intravenous use and

evaluation of its therapeutic efficacy in murine mycobacterium avium

infection. J Antimicrob Chemother 2000;45:77-83.

Jacobs C, Kayder O, Muller RH. Nanosuspensions as a new approach for the

formulation of poorly soluble drug tarazepide. Int J Pharm 2000;196:161-4.

Moschwitzer J, Achleitner G, Promper H, Muller RH. Development of

an intravenously injectable chemically stable aqueous omeprazole

formulation using nanosuspension technology. Eur J Pharm Biopharm


Muller RH, Jacobs C. Production and Characterization of Budenoside

nanosuspension for pulmonar y administration. Pharm Res


Pignatello R, Ricupero N, Bucolo C, Maugeri F, Maltese A, Puglisi G.

Preparation and characterization of Eudragit retard nanosuspensions

for the ocular delivery of cloricromene. AAPS Pharmscitech


Kayser O, Lemke A, Hernandz.Trejo N. The impact of Nanobiotechnology on the development of new drug delivery systems. Current Pharm Biotech 2005;6:3-5.

Shah T, Patel D, Hirani J, Amin AF. Nanosuspensions as a drug delivery

systems-A comprehensice review. Drug Del Tech 2007;7:42-53.

Kayser O. Nanosuspensions for the formulation of aphidicolin

to improve drug targeting effects against Leishmania infected

macrophages. Int J Pharm 2000;196:253-6.

Ponchel G, Montisci MJ, Dembri A, Durrer C, Duchêne. D. Mucoadhesion of colloidal particulate systems in the gastrointestinal tract. Eur J Pharm Biopharm 1997; 44:25-31.

Kayser O. A new approach for targeting to Cryptosporidium parvum

using mucoadhesive nanosuspensions: research and applications.

Int J Pharm 2001;214:83-5.